Modern Healthcare14h
Eli Lilly denies affiliation with Hims & Hers
Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical ...
Morgan Stanley says Hims branded tirzepatide margins likely well below compounds
After Hims & Hers (HIMS) announced yesterday that the company is broadening its weight loss offering to include Lilly’s (LLY) branded ...
Why Hims & Hers Health Stock Couldn't Beat the Market Today
Hims & Hers Health (NYSE: HIMS) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 ...
Hims & Hers to sell Lilly’s Zepbound
Hims shares gained as much as 14% in New York, their biggest gain since Feb. 19.
Hims & Hers stock slipped as investors were left unimpressed with its new weight-loss drug options
Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update that left investors unimpressed.
NBC Los Angeles1d
Hims & Hers shares rise as company adds new weight-loss medications to platform
Zepbound, Mounjaro and liraglutide are part of the class of weight loss medications called GLP-1s, which have exploded in ...
Zepbound Now Available Through Hims & Hers
Zepbound is made by drugmaker Eli Lilly. While Hims & Hers offers it for $1,899 per month, Lilly said the price on its own LillyDirect platform starts at $349 for self-paying customers. With insurance ...
Eli Lilly says company has no affiliation with Hims & Hers
In a statement on its website, Eli Lilly and Company (LLY) said it has no affiliation with hims & hers (HIMS). It added, “Zepbound can be ...
Why Hims & Hers Health Stock Soared Tuesday
Shares of Hims & Hers Health ( HIMS 5.01%) surged on Tuesday, closing the session up 5.25% after having been up by as much as ...